President and CEO, Emiliem, Inc. and Elara Bioscience Inc
Dr. Dale Johnson is an Adjunct Professor of Molecular Toxicology at UC Berkeley where he teaches Computational Toxicology, Principles of Drug Action, and lectures in Pharmacogenomics. He has had previous academic appointments at University of Michigan, Western Michigan University, and St. John’s University. He is also currently President & CEO of Emiliem, Inc. a start-up biotech company in California and Michigan. He has over 30 years experience in biopharmaceutical research and development activities where he has led and managed small units in start-up companies to multi-national groups in large corporations. He has participated in the research and development of over 100 investigational molecules of which 15 have become marketed medicinal products in the U.S., Europe, and Japan, and is co-inventor on 6 issued patents. He received BS, Pharm.D, and Ph.D (Toxicology). degrees from the University of Michigan where he was an AFPE Fellow. He is a Diplomate of the American Board of Toxicology (DABT). Dr. Johnson is the co-author of over 100 published papers, abstracts, and book chapters; was journal co-editor of The Chemistry of Metabolic and Toxicological Processes section of Current Opinion in Drug Discovery & Development; is the Special Issue Editor of Advances in Computational Toxicology, International Journal of Molecular Science; and is on the Editorial Advisory Board for the Wiley book series on Technologies for the Pharmaceutical Industry. He is a member of the Green Ribbon Science Panel for the state of California’s Department of Toxic Substances Control and is a member of scientific advisory boards for privately held companies. His current research activities are focused on creating and rolling out a comprehensive infrastructure designed to support all relevant and available chemical-toxicity resources, extend to various model systems and “omics” data sets, and be applicable to human health from chemical exposures and to early and late stage drug research and development. He is an active member of AAAS, American Chemical Society, and the Society of Toxicology.
He is currently applying this knowledge and expertise in academics, therapeutic R&D, as well as on environmental issues through the State of California Green Chemistry Initiatives. He is currently a member of the Green Ribbon Science Panel for California Department of Toxic Substances Control. He is a Diplomate of the American Board of Toxicology, co-inventor on several issued and pending patents, and co-editor of the journal The Chemistry of Metabolic and Toxicological Processes, Current Opinion in Drug Discovery & Development.